Bausch + Lomb Announces Expiration Of Hart-Scott-Rodino Waiting Period For Acquisition Of Xiidra, A Non-Steroid Eye Drop For Signs And Symptoms Of Dry Eye Disease
Portfolio Pulse from Benzinga Newsdesk
Bausch + Lomb, a subsidiary of Bausch Health Companies Inc., has announced the expiration of the Hart-Scott-Rodino waiting period for the acquisition of Xiidra, a non-steroid eye drop for signs and symptoms of dry eye disease.
August 24, 2023 | 11:14 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bausch Health Companies Inc.'s subsidiary Bausch + Lomb's acquisition of Xiidra has moved forward with the expiration of the Hart-Scott-Rodino waiting period.
The expiration of the Hart-Scott-Rodino waiting period is a significant step in the acquisition process, indicating that the deal is moving forward. This could potentially boost Bausch Health's portfolio and strengthen its position in the market, which may positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100